Literature DB >> 30270669

The national burden of periprosthetic hip fractures in the US: costs and risk factors for hospital readmission.

Russell A Reeves1, William W Schairer2, David S Jevsevar3.   

Abstract

INTRODUCTION: Periprosthetic hip fractures (PPFX) are serious complications that result in increased morbidity, mortality and healthcare costs. Decreasing hospital readmissions has been a recent healthcare focus, but little is known about the overall costs associated with PPFX or the risk factors associated with readmissions. We investigated patient demographics, treatment types, 30- and 90-day readmission rates, direct costs, and patient risk factors associated with PPFX readmission.
METHODS: We used the 2013 Nationwide Readmissions Database to select patients who underwent total hip arthroplasty (THA), revision THA, and PPFX treated with open reduction internal fixation (ORIF) or revision THA. Survival analysis was used to evaluate the 90-day all-cause hospital readmission rate, and risk factors were identified using a Cox proportional hazards model, adjusting for patient and hospital characteristics.
RESULTS: We identified 1269 patients with PPFX treated with ORIF and 3254 treated with revision THA. 90-day readmissions were 20.9% and 27.3%, respectively. Patients with PPFX were older, female, and had multiple medical comorbidities. Patient factors associated with increased risk of readmission include: age; comorbidities; and discharge to skilled nursing facility; Medicare or Medicaid insurance. Hospital factors associated with increased risk of readmission include: large hospitals; nonprofits; metropolitan and teaching hospitals. The cost of readmission for PPFX treated with ORIF was $17,206 and revision THA was $16,504. DISCUSSION: Periprosthetic hip fractures have high rates of hospital readmission, implying a significant burden to the healthcare system. Identifying risk factors is an important step towards identifying treatment pathways that can improve outcomes.

Entities:  

Keywords:  Fracture fixation; health care costs; hip arthroplasty; orthopaedic; patient readmission; reoperation

Mesh:

Year:  2018        PMID: 30270669     DOI: 10.1177/1120700018803933

Source DB:  PubMed          Journal:  Hip Int        ISSN: 1120-7000            Impact factor:   2.135


  6 in total

1.  Incidence and risk factors of in-hospital prosthesis-related complications following total hip arthroplasty: a retrospective Nationwide Inpatient Sample database study.

Authors:  Qinfeng Yang; Jian Wang; Yichuan Xu; Yuhang Chen; Qiang Lian; Yang Zhang
Journal:  Int Orthop       Date:  2020-06-27       Impact factor: 3.075

2.  Predictors of falls in patients during the first year after total hip arthroplasty: A prospective cohort study.

Authors:  Kazunari Ninomiya; Naonobu Takahira; Takashi Ikeda; Koji Suzuki; Ryoji Sato; Kazuo Hirakawa
Journal:  Health Sci Rep       Date:  2020-08-19

3.  Projections and Epidemiology of Revision Hip and Knee Arthroplasty in the United States to 2030.

Authors:  Andrew M Schwartz; Kevin X Farley; George N Guild; Thomas L Bradbury
Journal:  J Arthroplasty       Date:  2020-02-19       Impact factor: 4.757

4.  Do standards of care and early outcomes of periprosthetic fractures change during the COVID-19 pandemic? A multicentre study.

Authors:  Luigi Zagra; Rocco D'Apolito; Nicola Guindani; Giovanni Zatti; Fabrizio Rivera; Flavio Ravasi; Mario Mosconi; Alberto Momoli; Alessandro Massè; Massimo Franceschini; Fabio D'Angelo; Dante Dallari; Fabio Catani; Alessandro Casiraghi; Federico Bove; Claudio Carlo Castelli
Journal:  J Orthop Traumatol       Date:  2021-06-14

5.  Demographics, Treatment, and Cost of Periprosthetic Femur Fractures: Fixation Versus Revision.

Authors:  Katelyn Ragland; Rebecca Reif; Saleema Karim; Kevin W Sexton; Steven M Cherney; Jeffrey B Stambough; Simon C Mears
Journal:  Geriatr Orthop Surg Rehabil       Date:  2020-07-19

6.  Factors influencing results and complications in proximal periprosthetic femoral fractures: a retrospective study at 1- to 8-year follow-up.

Authors:  Chiara Concina; Marina Crucil; Franco Gherlinzoni
Journal:  Acta Biomed       Date:  2021-07-26
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.